<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00723112</url>
  </required_header>
  <id_info>
    <org_study_id>20716</org_study_id>
    <secondary_id>DK007115-31</secondary_id>
    <nct_id>NCT00723112</nct_id>
  </id_info>
  <brief_title>The Role of Erythropoietin in Myelodysplastic Syndrome</brief_title>
  <official_title>The Role of Erythropoietin in Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to elucidate the causative molecular events responsible for the
      abnormal erythropoiesis in MDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myelodysplastic syndromes are a heterogeneous group of disorders characterized by clonal
      expansion of hematopoietic stem cells and ineffective hematopoiesis. Although all 3 cell
      lineages in myeloid hematopoiesis can be involved, the erythroid dysplasia and ineffective
      erythropoiesis of MDS are usually the most severe, and often precede the development of other
      bone marrow lineage defects.

      In normal erythropoiesis, erythroid progenitors differentiate and proliferate in response to
      stimulation by erythropoietin (Epo). Epo binds to its receptor, EpoR, constitutively
      expressed at the surface of committed erythroid progenitors and induces homodimerization.
      This study is designed to evaluate the EpoR cDNA sequence and its level of expression in the
      clonal erythroid progenitors of MDS patients (in cells stratified for the same degree of
      erythroid maturation) to determine whether mutations in the EpoR may be responsible for an
      aberrant Epo signal transduction in MDS. As well as analyze intrinsic erythroid Epo
      expression to determine whether it differs between normal controls and patients with MDS and
      perform a microarray analysis of genes associated with Epo signal transduction to determine
      if MDS patients have abnormal expression of signal transduction proteins.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the EpoR cDNA sequence and its level of expression in the clonal erythroid progenitors of MDS patients to determine whether mutations in the EpoR may be responsible for an aberrant Epo signal transduction in MDS.</measure>
    <time_frame>After Samples are obtained</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analyze intrinsic erythroid Epo expression to determine whether it differs between normal controls and patients with MDS.</measure>
    <time_frame>After samples are obtained</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perform a microarray analysis of genes associated with Epo signal transduction to determine if MDS patients have abnormal expression of signal transduction proteins.</measure>
    <time_frame>After samples are obtained</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine how often and what percent clonality occurs in MDS patients and try to predict who has early MDS by clonality testing.</measure>
    <time_frame>After samples from female patients have been obtained</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">8</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Affected Group</arm_group_label>
    <description>Adult subjects with the diagnosis of MDS based on the French-American-British classification system.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Control subjects will be selected using frequency matching on gender and age by decade. That is for each MDS patient a healthy volunteer of the same gender and decade (50-59, 60-69, 70-79, etc) will be selected</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects diagnosed with myelodysplastic syndrome
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects greater than 18 years of age

          -  Diagnosis of MDS based on the French-American-British classification system (including
             secondary causes of MDS)

        Exclusion Criteria:

          -  Subjects not meeting the criteria listed above
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef T Prchal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Salt Lake City Health Care System</name>
      <address>
        <city>Salt lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aul C, Arning M, Runde V, Schneider W. Serum erythropoietin concentrations in patients with myelodysplastic syndromes. Leuk Res. 1991;15(7):571-5.</citation>
    <PMID>1861540</PMID>
  </reference>
  <reference>
    <citation>Stasi R, Brunetti M, Terzoli E, Abruzzese E, Amadori S. Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing. Ann Oncol. 2004 Nov;15(11):1684-90.</citation>
    <PMID>15520072</PMID>
  </reference>
  <reference>
    <citation>Casadevall N, Durieux P, Dubois S, Hemery F, Lepage E, Quarr√© MC, Damaj G, Giraudier S, Guerci A, Laurent G, Dombret H, Chomienne C, Ribrag V, Stamatoullas A, Marie JP, Vekhoff A, Maloisel F, Navarro R, Dreyfus F, Fenaux P. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood. 2004 Jul 15;104(2):321-7. Epub 2004 Mar 30.</citation>
    <PMID>15054036</PMID>
  </reference>
  <reference>
    <citation>Solignac M; European Hematology Association. [Epoetin beta, new strategies to optimise the management of anaemia in cancer patients]. Presse Med. 2003 Sep 13;32(29):1385-8. French.</citation>
    <PMID>14534506</PMID>
  </reference>
  <reference>
    <citation>Fontenay-Roupie M, Bouscary D, Guesnu M, Picard F, Melle J, Lacombe C, Gisselbrecht S, Mayeux P, Dreyfus F. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br J Haematol. 1999 Aug;106(2):464-73.</citation>
    <PMID>10460607</PMID>
  </reference>
  <reference>
    <citation>Takeshita A, Shinjo K, Naito K, Ohnishi K, Higuchi M, Ohno R. Erythropoietin receptor in myelodysplastic syndrome and leukemia. Leuk Lymphoma. 2002 Feb;43(2):261-4. Review.</citation>
    <PMID>11999556</PMID>
  </reference>
  <reference>
    <citation>Shinjo K, Takeshita A, Higuchi M, Ohnishi K, Ohno R. Erythropoietin receptor expression on human bone marrow erythroid precursor cells by a newly-devised quantitative flow-cytometric assay. Br J Haematol. 1997 Mar;96(3):551-8.</citation>
    <PMID>9054663</PMID>
  </reference>
  <reference>
    <citation>McMullin MF, Percy MJ. Erythropoietin receptor and hematological disease. Am J Hematol. 1999 Jan;60(1):55-60. Review.</citation>
    <PMID>9883806</PMID>
  </reference>
  <reference>
    <citation>Kralovics R, Sokol L, Broxson EH Jr, Prchal JT. The erythropoietin receptor gene is not linked with the polycythemia phenotype in a family with autosomal dominant primary polycythemia. Proc Assoc Am Physicians. 1997 Nov;109(6):580-5.</citation>
    <PMID>9394420</PMID>
  </reference>
  <reference>
    <citation>Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood. 1997 Sep 1;90(5):2057-61.</citation>
    <PMID>9292543</PMID>
  </reference>
  <reference>
    <citation>Stopka T, Zivny JH, Stopkova P, Prchal JF, Prchal JT. Human hematopoietic progenitors express erythropoietin. Blood. 1998 May 15;91(10):3766-72.</citation>
    <PMID>9573013</PMID>
  </reference>
  <reference>
    <citation>Sato TN. A new role of lipid receptors in vascular and cardiac morphogenesis. J Clin Invest. 2000 Oct;106(8):939-40.</citation>
    <PMID>11032853</PMID>
  </reference>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2008</study_first_submitted>
  <study_first_submitted_qc>July 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2008</study_first_posted>
  <last_update_submitted>November 22, 2010</last_update_submitted>
  <last_update_submitted_qc>November 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Josef T. Prchal, MD</name_title>
    <organization>University of Utah</organization>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Erythropoiesis</keyword>
  <keyword>Ineffective Hematopoiesis</keyword>
  <keyword>Erythroid Progenitors</keyword>
  <keyword>Dyserythropoiesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

